Mr Imaging: Clinical Trials

4 trials of Mr Imaging, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 suspended. 4 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 34Suspended 4
Phase 23Suspended 3

Follow Mr Imaging: new trials by email Literature Review of Mr Imaging trials Research Report on Mr Imaging

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
Biospecimen Collection, Cemiplimab, Computed Tomography - Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma
Phase 3SuspendedNational Cancer Institute (NCI)4202025-02-182026-11-03
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Bone Scan, Cabozantinib S-malate, Cisplatin - High Grade Osteosarcoma, Localized Osteosarcoma
Phase 2 / Phase 3SuspendedNational Cancer Institute (NCI)11222023-03-032026-10-27
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Atezolizumab, Biospecimen Collection, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma
Phase 2 / Phase 3SuspendedNational Cancer Institute (NCI)1382021-01-072026-10-29
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Atezolizumab, Biopsy Procedure, Biospecimen Collection - Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Phase 2 / Phase 3SuspendedNational Cancer Institute (NCI)6132013-03-222026-11-02

Conditions studied

Osteosarcoma (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)

Sponsors

National Cancer Institute (NCI) (4)

Countries

United States (4)  ·  Canada (3)  ·  Australia (2)  ·  Hong Kong (1)  ·  New Zealand (1)

Top investigators

Michael W Bishop (1)  ·  Neil D Gross (1)  ·  Paul M Harari (1)  ·  Quynh-Nhu Nguyen (1)

Results publications

PMID 41137728, PMID 41671459

NIH funding

U10CA180868 (3), U10CA021661 (1), U10CA180886 (1)